Chen Yuzhu, Qi Fei, Sun Chenhao, Jiang Peng, Xue Xiangyu, Yang Xiaomei, Li Xiaomi, He Xin, Wang Yishuo, Zhang Tongmei
Department of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
Ther Adv Med Oncol. 2025 Jan 8;17:17588359241312501. doi: 10.1177/17588359241312501. eCollection 2025.
Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, despite these promising results, there is ongoing debate regarding the efficacy of immunological combination therapy strategies, the prevalence of treatment-related side effects, the identification of predictive biomarkers, and various other challenges within the neoadjuvant context. Careful consideration is essential to maximize the benefits of immunotherapy for patients with resectable NSCLC. This article offers a detailed overview of recent advancements in neoadjuvant immunotherapy for resectable NSCLC. By examining these developments, we aim to provide new perspectives and valuable insights into the benefits and challenges of applying neoadjuvant immunotherapy in clinical settings.
近年来，随着免疫检查点抑制剂在非小细胞肺癌（NSCLC）中的应用，人们的关注日益集中于此。大量临床研究强调了免疫疗法在治疗可切除NSCLC方面的潜力，突出了其在改善患者预后中的作用。然而，尽管取得了这些令人鼓舞的结果，但在新辅助治疗背景下，关于免疫联合治疗策略的疗效、治疗相关副作用的发生率、预测性生物标志物的识别以及其他各种挑战仍存在持续争论。为了使可切除NSCLC患者从免疫疗法中获得最大益处，仔细考虑至关重要。本文详细概述了可切除NSCLC新辅助免疫治疗的最新进展。通过审视这些进展，我们旨在为在临床环境中应用新辅助免疫治疗的益处和挑战提供新的视角和有价值的见解。
